Examkin

Soru

Zorluk: OrtaRheumatology and Immunology

A 45-year-old woman is newly diagnosed with moderate-to-severe, seropositive rheumatoid arthritis. She has no significant past medical history, normal hepatic and renal function, and no contraindications to standard pharmacotherapies. Assuming she requires continuous escalation of therapy due to inadequate responses at each step and ultimately develops severe, end-stage structural damage in her right knee over many years, arrange the following management steps in the correct chronological sequence.

  1. 1Initiate conventional synthetic DMARD monotherapy with methotrexate
  2. 2Add a biologic DMARD, such as a tumor necrosis factor (TNF) alpha inhibitor
  3. 3Switch to a biologic DMARD with a different mechanism of action
  4. 4Refer for surgical total joint arthroplasty

Cevap

The correct sequence of management is: 1) Initiate conventional synthetic DMARD monotherapy with methotrexate, 2) Add a tumor necrosis factor (TNF) alpha inhibitor, 3) Switch to a biologic DMARD with a different mechanism of action, 4) Refer for surgical total joint arthroplasty.
The standard stepwise approach to rheumatoid arthritis begins with conventional synthetic DMARDs (methotrexate), escalates to a biologic DMARD (often a TNF inhibitor) upon inadequate response, switches to a non-TNF biologic upon subsequent failure, and ultimately relies on surgical joint replacement for irreversible, end-stage structural damage.

Adım Adım Çözüm

1
Identify the appropriate first-line therapy for newly diagnosed, moderate-to-severe rheumatoid arthritis.
Methotrexate monotherapy is selected.
Methotrexate is the foundational initial disease-modifying agent due to its well-established long-term efficacy, safety profile, and cost-effectiveness.
2
Determine the next pharmacological step after an inadequate response to initial monotherapy.
Addition of a biologic DMARD (e.g., TNF inhibitor).
Guidelines recommend stepping up therapy by adding a biologic DMARD when disease activity remains unacceptably high despite maximally tolerated methotrexate.
3
Determine the management approach for a patient who fails initial biologic therapy.
Switch to a biologic with a different mechanism of action.
Cycling to a different class of biologic (non-TNF) is generally more effective than trying a second TNF inhibitor in cases of primary primary treatment failure.
4
Address end-stage, irreversible joint destruction.
Referral for total joint arthroplasty.
When pharmacological therapy cannot reverse existing structural damage and the patient suffers from intractable mechanical pain and dysfunction, surgical replacement is indicated.

Anahtar Kavram

Stepwise escalation of pharmacotherapy and surgical management in rheumatoid arthritis.
Tahmini Süre:1m 0s
Bu soruyu puanla

Konular

Rheumatology and Immunology

Bu konudan daha fazla soru